CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...
Zacks.com on MSN2d
CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell?Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...
"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...
CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...
AZoLifeSciences on MSN2d
Integrating CRISPR and biomaterials engineering: Paving the way for safer gene therapiesLehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...
A ruthenium catalyst facilitated the polymerization, or polymer addition. Industrial firms have used this catalyst to make ...
Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...
The scientific team at the laboratory is headed by a group of women with a track record in genomic science, molecular ...
Researchers at the Experimental and Clinical Research Center in Berlin are developing a targeted treatment for muscular ...
CrisprBits opens Research and Innovation Centre for CRISPR Gene Editing and Diagnostics in Bengaluru
Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and diagnostics ...
Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback